EE05196B1 - Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid - Google Patents

Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid

Info

Publication number
EE05196B1
EE05196B1 EEP200300558A EEP200300558A EE05196B1 EE 05196 B1 EE05196 B1 EE 05196B1 EE P200300558 A EEP200300558 A EE P200300558A EE P200300558 A EEP200300558 A EE P200300558A EE 05196 B1 EE05196 B1 EE 05196B1
Authority
EE
Estonia
Prior art keywords
lsulfon
anthranilamides
heteroar
medicaments
chain
Prior art date
Application number
EEP200300558A
Other languages
English (en)
Estonian (et)
Inventor
Brendel Joachim
Bhme Thomas
Peukert Stefan
Kleemann Heinz-Werner
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200300558A publication Critical patent/EE200300558A/xx
Publication of EE05196B1 publication Critical patent/EE05196B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
EEP200300558A 2001-06-12 2002-05-31 Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid EE05196B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (2)

Publication Number Publication Date
EE200300558A EE200300558A (et) 2004-02-16
EE05196B1 true EE05196B1 (et) 2009-08-17

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300558A EE05196B1 (et) 2001-06-12 2002-05-31 Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid

Country Status (41)

Country Link
US (2) US6903216B2 (zh)
EP (1) EP1399423B9 (zh)
JP (1) JP4422477B2 (zh)
KR (1) KR100863924B1 (zh)
CN (1) CN1247544C (zh)
AR (1) AR036045A1 (zh)
AT (1) ATE378318T1 (zh)
AU (1) AU2002316939B2 (zh)
BG (1) BG108415A (zh)
BR (1) BR0210374A (zh)
CA (1) CA2450076C (zh)
CO (1) CO5540283A2 (zh)
CR (1) CR7140A (zh)
CY (1) CY1107427T1 (zh)
CZ (1) CZ20033361A3 (zh)
DE (2) DE10128331A1 (zh)
DK (1) DK1399423T3 (zh)
EC (1) ECSP034883A (zh)
EE (1) EE05196B1 (zh)
ES (1) ES2295360T3 (zh)
HK (1) HK1065316A1 (zh)
HR (1) HRP20031028A2 (zh)
HU (1) HUP0400159A3 (zh)
IL (2) IL159247A0 (zh)
MA (1) MA27037A1 (zh)
MX (1) MXPA03010875A (zh)
MY (1) MY138341A (zh)
NO (1) NO20035450D0 (zh)
NZ (1) NZ530081A (zh)
OA (1) OA12631A (zh)
PE (1) PE20021066A1 (zh)
PL (1) PL364371A1 (zh)
PT (1) PT1399423E (zh)
RS (1) RS97703A (zh)
RU (1) RU2293727C2 (zh)
SK (1) SK15222003A3 (zh)
TN (1) TNSN03134A1 (zh)
TW (1) TWI304400B (zh)
UA (1) UA75412C2 (zh)
WO (1) WO2002100825A2 (zh)
ZA (1) ZA200308520B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
CN1659142A (zh) * 2002-04-26 2005-08-24 石原产业株式会社 吡啶化合物或其盐和含有它们的除草剂
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
MXPA06001550A (es) 2003-08-08 2006-09-04 Johnson & Johnson Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de a colecistocinina 2.
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP2012758A2 (en) * 2006-04-27 2009-01-14 Sanofi-Aventis Deutschland GmbH Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
SI2448909T1 (sl) * 2009-06-29 2013-07-31 Merz Pharma Gmbh & Co. Kgaa Postopek za pripravo 1-amino-1,3,3,5,5-pentametilcikloheksana
MX2012000256A (es) 2009-06-29 2012-04-19 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones.
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (zh) 2011-07-01 2018-04-28
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
JP7205830B2 (ja) * 2017-08-07 2023-01-17 国立大学法人広島大学 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
TR200103696T2 (tr) * 1999-06-24 2002-06-21 Smithkline Beecham Corporation Makrofaj temizleyici reseptör antagonistleri.
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
US6903216B2 (en) 2005-06-07
UA75412C2 (en) 2006-04-17
RS97703A (en) 2006-12-15
DK1399423T3 (da) 2008-03-17
WO2002100825A3 (de) 2003-12-11
BR0210374A (pt) 2004-07-13
AU2002316939B2 (en) 2006-11-23
EP1399423B9 (de) 2008-02-27
HK1065316A1 (en) 2005-02-18
HRP20031028A2 (en) 2005-10-31
CZ20033361A3 (cs) 2004-05-12
HUP0400159A3 (en) 2008-10-28
CO5540283A2 (es) 2005-07-29
ECSP034883A (es) 2004-01-28
BG108415A (en) 2004-07-30
PL364371A1 (en) 2004-12-13
KR20040030668A (ko) 2004-04-09
EP1399423B1 (de) 2007-11-14
NO20035450D0 (no) 2003-12-08
CN1247544C (zh) 2006-03-29
ES2295360T3 (es) 2008-04-16
TNSN03134A1 (en) 2005-12-23
HUP0400159A2 (hu) 2004-07-28
DE50211213D1 (de) 2007-12-27
PE20021066A1 (es) 2003-01-21
SK15222003A3 (sk) 2004-06-08
MXPA03010875A (es) 2004-02-17
CA2450076A1 (en) 2002-12-19
RU2293727C2 (ru) 2007-02-20
KR100863924B1 (ko) 2008-10-17
ZA200308520B (en) 2004-09-06
MY138341A (en) 2009-05-29
RU2004100302A (ru) 2005-04-10
CA2450076C (en) 2010-11-30
EP1399423A2 (de) 2004-03-24
US20050137200A1 (en) 2005-06-23
US7235664B2 (en) 2007-06-26
CN1529695A (zh) 2004-09-15
US20030114499A1 (en) 2003-06-19
IL159247A0 (en) 2004-06-01
AR036045A1 (es) 2004-08-04
WO2002100825A2 (de) 2002-12-19
JP4422477B2 (ja) 2010-02-24
PT1399423E (pt) 2008-02-07
OA12631A (fr) 2006-06-14
EE200300558A (et) 2004-02-16
TWI304400B (en) 2008-12-21
CY1107427T1 (el) 2012-12-19
ATE378318T1 (de) 2007-11-15
MA27037A1 (fr) 2004-12-20
IL159247A (en) 2010-06-16
JP2004533464A (ja) 2004-11-04
DE10128331A1 (de) 2002-12-19
CR7140A (es) 2004-04-15
NZ530081A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
EE05196B1 (et) Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
EE201300011A (et) Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
HUP0700086A2 (en) 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
IL154965A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
EE200300529A (et) Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
EE05424B1 (et) Asendatud asaindooloksoatseetpiperasiini derivaadid, neid sisaldav ravimpreparaat ning nende kasutamine ravis
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
NO20030627L (no) Hydrogel-drevet medikament doseringsform
EE200300110A (et) Kaneelhappe asendatud guanidiidid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav ravim
EE200100009A (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
EE200300574A (et) Aminokinoliini derivaadid, nende valmistamine, neid sisaldavad ravimkoostised ja nende kasutamine adenosiini A3-retseptori ligandidena

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110531